Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Søg efter ekspertise, navn eller tilknytning
Inna Chen
Herlev og Gentofte Hospital
,
Kræftbehandling
https://orcid.org/0000-0003-2891-0762
2016
2024
Publikationer pr. år
Vis
Fingeraftryk
Netværk
Publikationer
(47)
Lignende profiler
(12)
Fingeraftryk
Dyk ned i forskningsemnerne, hvor Inna Chen er aktive. Disse emneetiketter kommer fra dennes persons arbejder. Sammen danner de et unikt fingerprint.
Sorter
Vægt
Alfabetisk
Keyphrases
Pancreatic Ductal Adenocarcinoma
100%
Pancreatic Cancer
89%
Overall Survival
54%
Biliary Tract Cancer
34%
Circulating Proteins
33%
YKL-40
31%
Carbohydrate Antigen 19-9 (CA19-9)
29%
Nivolumab
27%
Resectable Pancreatic Cancer
27%
Ipilimumab
26%
Immune Checkpoint Inhibitors
26%
Tumor Fibrosis
25%
Metastatic Pancreatic Ductal Adenocarcinoma
25%
Propeptide
24%
PRO-C3
24%
Interleukin-6
23%
Phase II Study
23%
Stereotactic Body Radiotherapy
21%
Checkpoint Inhibitors
21%
Randomized Phase II Trial
21%
Confidence Interval
20%
Solid Tumors
19%
Prognostic Value
19%
Prognostic Biomarker
18%
Chemotherapy
18%
Type III Collagen
18%
Gemcitabine
16%
Inflammatory Biomarkers
16%
Resection
16%
C-reactive Protein
16%
Diagnostic Biomarker
15%
Radiotherapy
15%
PRO-C6
15%
Lung Cancer
15%
Protein Signature
14%
Randomized Controlled Trial
14%
Tocilizumab
13%
Metastatic Pancreatic Cancer
13%
Transforming Growth Factor-β
13%
Biomarker Potential
13%
Protein Biomarkers
13%
Tumor Microenvironment
12%
Tumor Subtype
11%
Fibroblasts
11%
Older Patients
11%
Healthy Controls
11%
Serum Levels
10%
Fibroblast Activity
10%
Hazard Ratio
10%
Combination Chemotherapy
10%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
97%
Pancreas Adenocarcinoma
70%
Biological Marker
67%
Overall Survival
49%
Neoplasm
32%
Immune Checkpoint Inhibitor
30%
Fibrosis
26%
Malignant Neoplasm
24%
Chemotherapy
21%
Solid Malignant Neoplasm
21%
Nivolumab
19%
Ipilimumab
19%
Collagen Type 3
17%
Disease
15%
Gemcitabine
15%
Interleukin 6
14%
C Reactive Protein
14%
Biliary Tract Cancer
14%
Colitis
13%
Tocilizumab
13%
Tumor Microenvironment
11%
CA 19-9 Antigen
11%
Fibrillar Collagen
10%
Pancreas Disease
8%
Diarrhea
8%
Lung Cancer
7%
Adverse Event
7%
Tumor Growth
7%
Circulating Tumor DNA
7%
Vitamin D Deficiency
6%
Arthritis
6%
Comorbidity
6%
Adenocarcinoma
6%
Paclitaxel
6%
Capecitabine
6%
Cohort Study
6%
Long Term Survival
6%
Vitamin D
6%
Chronic Disease
6%
Placebo
6%
Interleukin 15
6%
Clinical Study
6%
Life Expectancy
6%
Collagen Type 5
6%
Hypovitaminosis D
6%
Hyaluronic Acid
6%
Mouse Model
6%
Progression Free Survival
6%
Monotherapy
6%
Enzyme-Linked Immunosorbent Assay
6%
Medicine and Dentistry
Pancreas Cancer
89%
Pancreas Adenocarcinoma
60%
Biological Marker
42%
Overall Survival
38%
Biliary Tract Cancer
27%
Nivolumab
25%
Ipilimumab
24%
Malignant Neoplasm
24%
Stereotactic Body Radiation Therapy
23%
Immune Checkpoint Inhibitor
21%
Gemcitabine
16%
Disease
16%
Neoplasm
16%
Randomized Controlled Trial
14%
Cancer Therapy
14%
Symptom
13%
Tocilizumab
13%
Adenocarcinoma
13%
Interleukin-6
12%
Surgery
12%
Diagnosis
11%
Interleukin 6
11%
Hazard Ratio
10%
Combination Chemotherapy
10%
Advanced Cancer
10%
Adjuvant Therapy
9%
Collagen Type 3
9%
Pancreas Disease
8%
Oncology
8%
Extracellular Matrix
8%
Long Term Survival
8%
Fibrosis
8%
Lung Cancer
8%
Radiation Therapy
7%
Adverse Event
7%
Solid Malignant Neoplasm
7%
Liver Metastasis
7%
Circulating Tumor DNA
7%
Exercise
7%
Immunotherapy
7%
Proportional Hazards Model
6%
Quality of Life
6%
Retrospective Cohort Study
6%
Pancreatic Surgery
6%
Symptomatic Treatment
6%
Metastatic Colorectal Cancer
6%
Fibroblast
6%
Capecitabine
6%
Interleukin 15
6%
Age Difference
6%
